So far, 2021 is proving to be a time for international transition in pharma. In the latest Pricentric INSIGHTS newsletter, we’re taking a closer look at new legislation and regulatory actions happening around the globe to help you prepare for what’s coming next this year.
Here are the top stories from January:
- Trump’s MFN Rule Roll-Out Stalled by California, Maryland Courts: District court judges in Maryland and Northern California have ruled to stall the implementation of President Donald Trump’s “Most Favored Nations (MFN)” rule that was supposed to take effect on January 1, 2021.
- BMS, Roche, AZ Lose Out as China Favors Domestic Companies in NRDL PD-1 Battle: In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 edition of the National Reimbursement Drug List (NRDL).
- UK Makes Moves Toward Reforming Rare Disease Framework: At the beginning of January 2021, the UK’s Department of Health and Social Care (DHSC) published a new UK Rare Disease Framework, with hopes that the structure will help improve care for those who have rare diseases.
Contact us with your questions and global pricing needs, and an expert will follow up shortly.
NAVLIN Price & Access Data is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level. Our…